TAVI patients with coronary artery disease can derive benefits from percutaneous coronary intervention

Plus, news about CSL Vi­for, Ake­bia and Pan Can­cer T: Faron gets FDA go-ahead for stream­lined reg­is­tra­tional path: The com­pa­ny said the reg­u­la­tor “ac­knowl­edged the

Spec­trum Lab­o­ra­to­ry Prod­ucts is the lat­est API man­u­fac­tur­er to re­ceive an FDA Form 483 fol­low­ing an in­spec­tion. The 483 in­cludes 14 de­fi­cien­cies from sev­en in­spec­tions